Erythropac Warnings

Erythromycin is excreted principally by the liver so caution should be exercised in administering the antibiotic to patients with impaired hepatic function or concomitantly receiving potentially hepatotoxic agents. Hepatic dysfunction including increased enzymes and/or cholestatic, hepatitis with or without jaundice has been infrequently reported with erythromycin. There have been reports suggesting erythromycin does not reach the foetus with adequate concentrations to prevent congenital syphilis. Infants born to women treated during pregnancy with oral erythromycin for early syphilis should be treated with an appropriate penicillin regimen. There have been reports that erythromycin may aggravate the weakness of patients with myasthenia gravis.
Erythromycin interferes with the fluorometric determination of urinary catecholamines. As with other broad spectrum antibiotics, pseudomembranous colitis has been reported rarely with erythromycin.
Rhabdomyolysis with or without renal impairment has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin.